Chemistry: analytical and immunological testing – Nuclear magnetic resonance – electron spin resonance or other...
Reexamination Certificate
2011-03-15
2011-03-15
Gakh, Yelena G (Department: 1777)
Chemistry: analytical and immunological testing
Nuclear magnetic resonance, electron spin resonance or other...
C436S086000, C436S171000, C435S006120, C435S069900, C435S372000, C702S020000, C702S179000
Reexamination Certificate
active
07906342
ABSTRACT:
Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.
REFERENCES:
patent: 7736905 (2010-06-01), Roder et al.
patent: 2005/0048547 (2005-03-01), Zhao et al.
patent: 2005/0164218 (2005-07-01), Agus et al.
patent: 2005/0267689 (2005-12-01), Tsypin
patent: 2006/0029574 (2006-02-01), Albitar et al.
patent: 2007/0231921 (2007-10-01), Röder et al.
patent: WO 2004/012588 (2004-02-01), None
patent: WO 2005/010492 (2005-02-01), None
patent: WO 2005/098445 (2005-10-01), None
Extended European Search Report dated Aug. 25, 2010 in European Application No. 10003343.0.
Reyzer et al.MALDI mass spectrometry for direct tissue analysis: a new tool for biomarker discovery, Journal of Proteome Research vol. 4, No. 4, pp. 1138-1142 (2005).
Yanagisawa et al.Proteomic patterns of tumour subsets in non-small-cell lung cancer, The Lancet, vol. 362, pp. 433-439 (Aug. 9, 2003).
Extended European Search Report in EP 07754043.3, dated Aug. 6, 2009.
Bhanot et al.,A Robust Meta-Classification Strategy for Cancer Detection from MS Data, Proteomics, vol. 6, pp. 592-604 (2006).
Metro, et al., “Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)”, Reviews on Recent Clinical Trials, vol. 1, No. 1, pp. 1-13 (2006).
Taguchi, et al., “Mass Spectrometry to Classify Non-Small-Cell Lung Cancer Patients for Clinical Outcome after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study”, Journal of the National Cancer Institute, vol. 99, Issue 11, pp. 838-846 (2007).
Ladanyi, et al., “Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond”, Modern Pathology, vol. 21, pp. S16-S22 (2008).
Engelman et al.Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer, Clin. Cancer Res. 2008; 14(10) pp. 2895-2899 (May 15, 2008).
Lynch et al.,Activating Mutations in the Epiderman Growth Factor Receptor Underlying Responsiveness of Non-Small-Call lung Cancer to Getfitinib, The New England Journal of Medicine, May 20, 2004, vol. 350, No. 21, pp. 2129-2139 (2004).
Howard et al.Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis, Proteomics vol. 3, pp. 1720-1724 (2003).
D. Coomans and D.L. Massart,Alternative k-Nearest Neighbour Rules in Supervised Pattern Recognition, Part 1, Analytica Chimica Acta, 136, pp. 15-27 (1982).
Office Action in EP application No. 07754043.3 dated Sep. 14, 2010.
Bhanot et al.A robust meta-classification strategy for cancer detection from MS data Proteomics, vol. 6, NR 2, pp. 592-607 (Jan. 2006).
U.S. Appl. No. 12/661,129, filed Mar. 10, 2010, Roder et al.
U.S. Appl. No. 12/661,124, filed Mar. 10, 2010, Roder et al.
U.S. Appl. No. 12/321,394, filed Jan. 20, 2009, Roder et al.
U.S. Appl. No. 12/321,393, filed Jan. 20, 2009, Roder et al.
U.S. Appl. No. 12/321,392, filed Jan. 20, 2009, Roder et al.
Grigorieva Julia
Röder Heinrich
Tsypin Maxim
Biodesix, Inc.
Gakh Yelena G
McDonnell Boehnen & Hulbert & Berghoff LLP
Xu Robert
LandOfFree
Monitoring treatment of cancer patients with drugs targeting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monitoring treatment of cancer patients with drugs targeting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monitoring treatment of cancer patients with drugs targeting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2682054